Save 20% on your order with code
K4 Elite logo K4 Elite
Home / Research Trials / BPC-157 + TB-500 blend
Blend — no combined trials

BPC-157 + TB-500 blend

Healing & Recovery · listed as BPC-157 + TB-500

No controlled human study of the BPC-157 + TB-500 combination exists. The combination has been tested once in animals: a 2026 rat Achilles-tendon transection study (Biçer et al.) gave BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both intraperitoneally for four weeks and found the combination conferred no additional benefit over either agent alone. A 2021 retrospective chart review of 17 knee-pain patients described intra-articular BPC 157 'alone or combined with thymosin beta-4' (full-length, not the fragment) with only a telephone pain survey and no control group. Component evidence is summarised in the individual entries; FDA Category 2 statements cover both components.

No combined trials1 reported adverse effect0 documented interactions4 references
🔬 Research use only — not for human or veterinary use. The regimens below are records of what published studies administered to their own subjects; they are not instructions and K4 Elite does not provide dosing instructions.
Published trial usage Adverse effects Interactions Contraindications References
Published trial usage

No controlled studies of this combination exist

No randomised, controlled or otherwise comparative study of this multi-component preparation as a combination has been published, in humans or in animals. There is therefore no trial regimen, no combined safety dataset and no interaction dataset to report for the blend itself.

What has been published concerns the individual components, each of which has its own record:

BPC-157Preclinical onlyTB-500 (Thymosin beta-4 fragment, Ac-LKKTETQ)Preclinical only
Reported adverse effects

Effects recorded in the cited reports. Frequencies are those the source reported, in the population that source studied.

EffectFrequency / contextSource
No controlled adverse-event data exist for the combination In the single rat combination study, no toxicity outcomes were reported; the uncontrolled human knee-pain chart review did not systematically collect adverse events. FDA has no human exposure data for the TB-500 fragment and limited data for BPC-157. FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗
Interactions

No interactions with a verifiable citation have been indexed for this compound.

Contraindications noted in trials

Exclusions and label contraindications recorded in the cited sources.

References
  1. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study, Jt Dis Relat Surg 2026
  2. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain, Altern Ther Health Med 2021 (retrospective, uncontrolled; BPC 157 alone or with full-length Tβ4)
  3. Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026
  4. FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 list)
Elsewhere on K4 Elite
BPC-157 + TB-500 - Wolverine Stack — product pageAll indexed compounds — Research Trials
Research use only. This record summarises published literature for reference. It is not medical advice, not a protocol, and not a recommendation to administer this compound to any subject. Regimens are reported as the historical record of how a cited study was conducted; findings are reported without interpretation and constitute no claim of safety or efficacy. Determining any research procedure is the sole responsibility of the qualified researcher. Products referenced on this site are supplied strictly for in-vitro laboratory and research purposes, are not for diagnostic or therapeutic use, and have not been evaluated by the FDA.